Literature DB >> 19756924

The impact of sentinel lymph node biopsy in patients with a core biopsy diagnosis of ductal carcinoma in situ.

Wai Ka Hung1, Marcus Ying, Miranda Chan, Kong Ling Mak, Lap Kin Chan.   

Abstract

BACKGROUND: When ductal carcinoma in situ (DCIS) is found on core biopsy, histological underestimation can occur due to sampling error. When an invasive cancer is subsequently found, another operation is required for nodal staging. Sentinel lymph node biopsy (SLNB) enables nodal staging at the same operation. We examine the value of SLNB in patients with a preoperative diagnosis of DCIS focusing on the need for reoperation.
METHODS: Patients with a preoperative core biopsy of DCIS underwent SLNB at the time of definitive surgery. The results of SLNB in relation to histological upstaging were analyzed.
RESULTS: One hundred and seven patients with a core biopsy diagnosis of DCIS underwent simultaneous SLNB at the time of definitive surgery. SLNB was successful in 103 patients (96.3%) and 12 (11.7%) had SLN metastases. Thirty-two patients (29.9%) had histological upstaging and SLN was positive in nine (28.1%). Seventy-five patients had "pure DCIS" but three (4%) had SLN metastases. The presence of a palpable mass and radiological mass lesion were associated with histological upstaging. If SLNB were not performed, 32 patients (29.9%) with upstaging would require another surgery to stage the axilla. In the present series, 84% of these patients had appropriate axillary staging without the need for a second operation.
CONCLUSION: Underestimation of invasive disease was frequent on core biopsy. Performing SLNB during definitive surgery allowed correct nodal staging in a single operation. SLN metastasis was rare in patients with "pure DCIS" on final pathology. However, additional systemic treatment may be indicated for patients with SLN micrometastases.

Entities:  

Mesh:

Year:  2009        PMID: 19756924     DOI: 10.1007/s12282-009-0164-2

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  6 in total

1.  Detection of invasive components in cases of breast ductal carcinoma in situ on biopsy by using apparent diffusion coefficient MR parameters.

Authors:  Naoko Mori; Hideki Ota; Shunji Mugikura; Chiaki Takasawa; Junya Tominaga; Takanori Ishida; Mika Watanabe; Kei Takase; Shoki Takahashi
Journal:  Eur Radiol       Date:  2013-06-04       Impact factor: 5.315

2.  Sonoelastographic lesion stiffness: preoperative predictor of the presence of an invasive focus in nonpalpable DCIS diagnosed at US-guided needle biopsy.

Authors:  Nariya Cho; Woo Kyung Moon; Jung Min Chang; Ann Yi; Hye Ryoung Koo; Jeong-Seon Park; In Ae Park
Journal:  Eur Radiol       Date:  2011-03-13       Impact factor: 5.315

3.  Prediction of invasive breast cancer using shear-wave elastography in patients with biopsy-confirmed ductal carcinoma in situ.

Authors:  Jae Seok Bae; Jung Min Chang; Su Hyun Lee; Sung Ui Shin; Woo Kyung Moon
Journal:  Eur Radiol       Date:  2016-04-16       Impact factor: 5.315

4.  Breast Lesions Diagnosed as Ductal Carcinoma In Situ by Ultrasound-Guided Core Needle Biopsy: Risk Predictors for Concomitant Invasive Carcinoma and Axillary Lymph Node Metastasis.

Authors:  Yanbiao Liu; Xu Wang; Ang Zheng; Xinmiao Yu; Zining Jin; Feng Jin
Journal:  Front Oncol       Date:  2021-09-10       Impact factor: 6.244

5.  Axillary evaluation is not warranted in patients preoperatively diagnosed with ductal carcinoma in situ by core needle biopsy.

Authors:  Jing Si; Rong Guo; Naisi Huang; Bingqiu Xiu; Qi Zhang; Weiru Chi; Jiong Wu
Journal:  Cancer Med       Date:  2019-10-29       Impact factor: 4.452

6.  Turbo Spin-echo Diffusion-weighted Imaging Compared with Single-shot Echo-planar Diffusion-weighted Imaging: Image Quality and Diagnostic Performance When Differentiating between Ductal Carcinoma in situ and Invasive Ductal Carcinoma.

Authors:  Naoko Mori; Shunji Mugikura; Minoru Miyashita; Yu Mori; Yui Maekawa; Tatsuo Nagasaka; Kei Takase
Journal:  Magn Reson Med Sci       Date:  2020-03-06       Impact factor: 2.471

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.